FILING ANALYSIS · THURSDAY, OCTOBER 15
INTERPACE BIOSCIENCES, INC. IDXG — 8-K: Results of Operations and Financial Condition
neutral
Interpace Biosciences announced preliminary Q3 revenue of $10.1-10.4 million, representing 11-14% quarter-over-quarter growth and 15-18% year-over-year growth, but this is preliminary and unaudited, subject to completion of quarter-end closing procedures and review by the independent auditor.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →